Cargando…

Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19

The COVID-19 pandemic continues to have a devastating impact on health systems and economies across the globe. Implementing public health measures in tandem with effective vaccination strategies have been instrumental in curtailing the burden of the pandemic. With the three vaccines authorized for u...

Descripción completa

Detalles Bibliográficos
Autores principales: Taboe, Hemaho B., Asare-Baah, Michael, Iboi, Enahoro A., Ngonghala, Calistus N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933549/
https://www.ncbi.nlm.nih.gov/pubmed/36803672
http://dx.doi.org/10.1016/j.mbs.2023.108981
_version_ 1784889703788445696
author Taboe, Hemaho B.
Asare-Baah, Michael
Iboi, Enahoro A.
Ngonghala, Calistus N.
author_facet Taboe, Hemaho B.
Asare-Baah, Michael
Iboi, Enahoro A.
Ngonghala, Calistus N.
author_sort Taboe, Hemaho B.
collection PubMed
description The COVID-19 pandemic continues to have a devastating impact on health systems and economies across the globe. Implementing public health measures in tandem with effective vaccination strategies have been instrumental in curtailing the burden of the pandemic. With the three vaccines authorized for use in the U.S. having varying efficacies and waning effects against major COVID-19 strains, understanding the impact of these vaccines on COVID-19 incidence and fatalities is critical. Here, we formulate and use mathematical models to assess the impact of vaccine type, vaccination and booster uptake, and waning of natural and vaccine-induced immunity on the incidence and fatalities of COVID-19 and to predict future trends of the disease in the U.S. when existing control measures are reinforced or relaxed. The results show a 5-fold reduction in the control reproduction number during the initial vaccination period and a 1.8-fold (2-fold) reduction in the control reproduction number during the initial first booster (second booster) uptake period, compared to the respective previous periods. Due to waning of vaccine-induced immunity, vaccinating up to 96% of the U.S. population might be required to attain herd immunity, if booster uptake is low. Additionally, vaccinating and boosting more people from the onset of vaccination and booster uptake, especially with the Pfizer-BioNTech and Moderna vaccines (which confer superior protection than the Johnson & Johnson vaccine) would have led to a significant reduction in COVID-19 cases and deaths in the U.S. Furthermore, adopting natural immunity-boosting measures is important in fighting COVID-19 and transmission rate reduction measures such as mask-use are critical in combating COVID-19. The emergence of a more transmissible COVID-19 variant, or early relaxation of existing control measures can lead to a more devastating wave, especially if transmission rate reduction measures and vaccination are relaxed simultaneously, while chances of containing the pandemic are enhanced if both vaccination and transmission rate reduction measures are reinforced simultaneously. We conclude that maintaining or improving existing control measures, and boosting with mRNA vaccines are critical in curtailing the burden of the pandemic in the U.S.
format Online
Article
Text
id pubmed-9933549
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-99335492023-02-17 Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19 Taboe, Hemaho B. Asare-Baah, Michael Iboi, Enahoro A. Ngonghala, Calistus N. Math Biosci Original Research Article The COVID-19 pandemic continues to have a devastating impact on health systems and economies across the globe. Implementing public health measures in tandem with effective vaccination strategies have been instrumental in curtailing the burden of the pandemic. With the three vaccines authorized for use in the U.S. having varying efficacies and waning effects against major COVID-19 strains, understanding the impact of these vaccines on COVID-19 incidence and fatalities is critical. Here, we formulate and use mathematical models to assess the impact of vaccine type, vaccination and booster uptake, and waning of natural and vaccine-induced immunity on the incidence and fatalities of COVID-19 and to predict future trends of the disease in the U.S. when existing control measures are reinforced or relaxed. The results show a 5-fold reduction in the control reproduction number during the initial vaccination period and a 1.8-fold (2-fold) reduction in the control reproduction number during the initial first booster (second booster) uptake period, compared to the respective previous periods. Due to waning of vaccine-induced immunity, vaccinating up to 96% of the U.S. population might be required to attain herd immunity, if booster uptake is low. Additionally, vaccinating and boosting more people from the onset of vaccination and booster uptake, especially with the Pfizer-BioNTech and Moderna vaccines (which confer superior protection than the Johnson & Johnson vaccine) would have led to a significant reduction in COVID-19 cases and deaths in the U.S. Furthermore, adopting natural immunity-boosting measures is important in fighting COVID-19 and transmission rate reduction measures such as mask-use are critical in combating COVID-19. The emergence of a more transmissible COVID-19 variant, or early relaxation of existing control measures can lead to a more devastating wave, especially if transmission rate reduction measures and vaccination are relaxed simultaneously, while chances of containing the pandemic are enhanced if both vaccination and transmission rate reduction measures are reinforced simultaneously. We conclude that maintaining or improving existing control measures, and boosting with mRNA vaccines are critical in curtailing the burden of the pandemic in the U.S. Elsevier Inc. 2023-06 2023-02-16 /pmc/articles/PMC9933549/ /pubmed/36803672 http://dx.doi.org/10.1016/j.mbs.2023.108981 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Research Article
Taboe, Hemaho B.
Asare-Baah, Michael
Iboi, Enahoro A.
Ngonghala, Calistus N.
Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19
title Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19
title_full Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19
title_fullStr Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19
title_full_unstemmed Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19
title_short Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19
title_sort critical assessment of the impact of vaccine-type and immunity on the burden of covid-19
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933549/
https://www.ncbi.nlm.nih.gov/pubmed/36803672
http://dx.doi.org/10.1016/j.mbs.2023.108981
work_keys_str_mv AT taboehemahob criticalassessmentoftheimpactofvaccinetypeandimmunityontheburdenofcovid19
AT asarebaahmichael criticalassessmentoftheimpactofvaccinetypeandimmunityontheburdenofcovid19
AT iboienahoroa criticalassessmentoftheimpactofvaccinetypeandimmunityontheburdenofcovid19
AT ngonghalacalistusn criticalassessmentoftheimpactofvaccinetypeandimmunityontheburdenofcovid19